Testing the Persuasiveness of Pro-inoculation Arguments
NCT ID: NCT05804825
Last Updated: 2023-07-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
523 participants
INTERVENTIONAL
2023-05-04
2023-05-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Message Encouraging Vaccination in Preparation for the Holidays
NCT05612360
PreTeenVax Evaluation
NCT03186430
Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age
NCT05489328
A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years
NCT02955160
P3+ Intervention Phase
NCT02898688
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Simple forewarning message
Participants will receive a simple short forewarning message to read and rate.
Simple forewarning message
Participants will be presented with a simple forewarning message.
Argument inoculation messages
Participants will view a random sample of 3 text-only short messages (from a corpus of 100 arguments) to read and rate.
Argument inoculation messages
Participants will then be presented with arguments randomly selected by the Qualtrics software algorithm from the full set of messages.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Argument inoculation messages
Participants will then be presented with arguments randomly selected by the Qualtrics software algorithm from the full set of messages.
Simple forewarning message
Participants will be presented with a simple forewarning message.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age eligible child has not yet received any doses of the HPV vaccine
3. Resides in the United States
4. English speaking
5. Completed informed consent
Exclusion Criteria
2. Age \< 18
3. Does not have a child within the age range of 7-10
4. Age-eligible child has received 1 or more doses of the HPV vaccine
6. Unwilling or unable to provide informed consent to study participation
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Pennsylvania
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UPenn
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
dfjgehea
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.